Top Markets
Coin of the day
AstraZeneca PLC AstraZeneca PLC

AstraZeneca PLC

AZN
Classement en actions #159
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery,... AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Prix de l'action
$169.29
Capitalisation boursière
$131.27B
Changement (1 jour)
0.55%
Changement (1 an)
141.57%
Pays
GB
Échange AstraZeneca PLC (AZN)

Catégorie

Le prix AZN avec la capitalisation boursière de B
AstraZeneca PLC AstraZeneca PLC
AZN
$169.29
Capitalisation boursière de AstraZeneca PLC(AZN)
Capitalisation boursière: $131.27B
En July 2026, AstraZeneca PLC a une capitalisation boursière de $131.27B. Cela fait de AstraZeneca PLC la 159th entreprise la plus valorisée au monde selon nos données. La capitalisation boursière, souvent appelée market cap, correspond à la valeur totale des actions en circulation d’une entreprise cotée en bourse, et est couramment utilisée pour évaluer sa valeur.
Historique de la capitalisation boursière de AstraZeneca PLC du 1993 au 2026
AZN par rapport au top 5 des plus populaires stocks
Prix pour AZN L’actif B La capitalisation boursière de B Résultats
AstraZeneca PLC AstraZeneca PLC
$6,478.21 $131.27B
$5.023T +3,726.69%
AstraZeneca PLC AstraZeneca PLC
$6,312.20 $131.27B
$4.895T +3,628.63%
AstraZeneca PLC AstraZeneca PLC
$5,552.22 $131.27B
$4.305T +3,179.71%
AstraZeneca PLC AstraZeneca PLC
$3,842.41 $131.27B
$2.980T +2,169.72%
AstraZeneca PLC AstraZeneca PLC
$3,466.55 $131.27B
$2.688T +1,947.70%